Relationships Between Disease Activity and Serum and Fecal Biomarkers in Patients With Crohn's Disease

Jennifer Jones, Edward Vincent Loftus, Jr, Remo Panaccione, Li Sheng Chen, Sandra Peterson, Joseph Mcconnell, Linnea Baudhuin, Karen Hanson, Brian G. Feagan, Scott W. Harmsen, Alan R. Zinsmeister, Emelie Helou, William J. Sandborn

Research output: Contribution to journalArticle

261 Citations (Scopus)

Abstract

Background & Aims: The quantitative relationships between instruments and assays that measure clinical, endoscopic, and biologic disease activity in patients with Crohn's disease are poorly characterized. This study evaluated the correlations between the Crohn's Disease Activity Index (CDAI), the Simple Endoscopic Score for Crohn's Disease (SES-CD), serum high-sensitivity C-reactive protein (hsCRP) (both phenotype and genotype) and interleukin-6 (IL-6), and fecal calprotectin and lactoferrin. Methods: A total of 164 patients with Crohn's disease undergoing colonoscopy were enrolled. The CDAI and SES-CD scores, serum hsCRP and IL-6, CRP and IL-6 genotypes, and fecal calprotectin and lactoferrin were measured. Results: There were no significant associations between the CDAI and SES-CD scores (Spearman rank correlation coefficient, 0.15) or between the CDAI scores and the serum concentrations of hsCRP and IL-6, or the fecal concentrations of calprotectin and lactoferrin. In contrast, the serum hsCRP and IL-6 concentrations and the fecal calprotectin and lactoferrin concentrations were significantly higher in patients with more severe endoscopic disease activity (SES-CD score > 7 points) (P < .001 for all comparisons). The CRP 717 mutant homozygote and heterozygote status was associated with significantly lower concentrations of hsCRP (P = .02). There was a trend toward higher hsCRP concentrations in the CRP 286 heterozygous adenine mutant-type mutant genotype, but this did not reach statistical significance. Conclusions: Serum and fecal biomarker concentrations are associated with endoscopic but not clinical disease activity in patients with Crohn's disease. Stimulated hsCRP concentration is affected significantly by select genetic polymorphisms.

Original languageEnglish (US)
Pages (from-to)1218-1224
Number of pages7
JournalClinical Gastroenterology and Hepatology
Volume6
Issue number11
DOIs
StatePublished - Nov 2008

Fingerprint

Crohn Disease
Biomarkers
C-Reactive Protein
Leukocyte L1 Antigen Complex
Serum
Lactoferrin
Interleukin-6
Genotype
Homozygote
Genetic Polymorphisms
Adenine
Colonoscopy
Heterozygote
Nonparametric Statistics
Phenotype

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology

Cite this

Relationships Between Disease Activity and Serum and Fecal Biomarkers in Patients With Crohn's Disease. / Jones, Jennifer; Loftus, Jr, Edward Vincent; Panaccione, Remo; Chen, Li Sheng; Peterson, Sandra; Mcconnell, Joseph; Baudhuin, Linnea; Hanson, Karen; Feagan, Brian G.; Harmsen, Scott W.; Zinsmeister, Alan R.; Helou, Emelie; Sandborn, William J.

In: Clinical Gastroenterology and Hepatology, Vol. 6, No. 11, 11.2008, p. 1218-1224.

Research output: Contribution to journalArticle

Jones, J, Loftus, Jr, EV, Panaccione, R, Chen, LS, Peterson, S, Mcconnell, J, Baudhuin, L, Hanson, K, Feagan, BG, Harmsen, SW, Zinsmeister, AR, Helou, E & Sandborn, WJ 2008, 'Relationships Between Disease Activity and Serum and Fecal Biomarkers in Patients With Crohn's Disease', Clinical Gastroenterology and Hepatology, vol. 6, no. 11, pp. 1218-1224. https://doi.org/10.1016/j.cgh.2008.06.010
Jones, Jennifer ; Loftus, Jr, Edward Vincent ; Panaccione, Remo ; Chen, Li Sheng ; Peterson, Sandra ; Mcconnell, Joseph ; Baudhuin, Linnea ; Hanson, Karen ; Feagan, Brian G. ; Harmsen, Scott W. ; Zinsmeister, Alan R. ; Helou, Emelie ; Sandborn, William J. / Relationships Between Disease Activity and Serum and Fecal Biomarkers in Patients With Crohn's Disease. In: Clinical Gastroenterology and Hepatology. 2008 ; Vol. 6, No. 11. pp. 1218-1224.
@article{c966f14f74584da2818887b8cc8bdda5,
title = "Relationships Between Disease Activity and Serum and Fecal Biomarkers in Patients With Crohn's Disease",
abstract = "Background & Aims: The quantitative relationships between instruments and assays that measure clinical, endoscopic, and biologic disease activity in patients with Crohn's disease are poorly characterized. This study evaluated the correlations between the Crohn's Disease Activity Index (CDAI), the Simple Endoscopic Score for Crohn's Disease (SES-CD), serum high-sensitivity C-reactive protein (hsCRP) (both phenotype and genotype) and interleukin-6 (IL-6), and fecal calprotectin and lactoferrin. Methods: A total of 164 patients with Crohn's disease undergoing colonoscopy were enrolled. The CDAI and SES-CD scores, serum hsCRP and IL-6, CRP and IL-6 genotypes, and fecal calprotectin and lactoferrin were measured. Results: There were no significant associations between the CDAI and SES-CD scores (Spearman rank correlation coefficient, 0.15) or between the CDAI scores and the serum concentrations of hsCRP and IL-6, or the fecal concentrations of calprotectin and lactoferrin. In contrast, the serum hsCRP and IL-6 concentrations and the fecal calprotectin and lactoferrin concentrations were significantly higher in patients with more severe endoscopic disease activity (SES-CD score > 7 points) (P < .001 for all comparisons). The CRP 717 mutant homozygote and heterozygote status was associated with significantly lower concentrations of hsCRP (P = .02). There was a trend toward higher hsCRP concentrations in the CRP 286 heterozygous adenine mutant-type mutant genotype, but this did not reach statistical significance. Conclusions: Serum and fecal biomarker concentrations are associated with endoscopic but not clinical disease activity in patients with Crohn's disease. Stimulated hsCRP concentration is affected significantly by select genetic polymorphisms.",
author = "Jennifer Jones and {Loftus, Jr}, {Edward Vincent} and Remo Panaccione and Chen, {Li Sheng} and Sandra Peterson and Joseph Mcconnell and Linnea Baudhuin and Karen Hanson and Feagan, {Brian G.} and Harmsen, {Scott W.} and Zinsmeister, {Alan R.} and Emelie Helou and Sandborn, {William J.}",
year = "2008",
month = "11",
doi = "10.1016/j.cgh.2008.06.010",
language = "English (US)",
volume = "6",
pages = "1218--1224",
journal = "Clinical Gastroenterology and Hepatology",
issn = "1542-3565",
publisher = "W.B. Saunders Ltd",
number = "11",

}

TY - JOUR

T1 - Relationships Between Disease Activity and Serum and Fecal Biomarkers in Patients With Crohn's Disease

AU - Jones, Jennifer

AU - Loftus, Jr, Edward Vincent

AU - Panaccione, Remo

AU - Chen, Li Sheng

AU - Peterson, Sandra

AU - Mcconnell, Joseph

AU - Baudhuin, Linnea

AU - Hanson, Karen

AU - Feagan, Brian G.

AU - Harmsen, Scott W.

AU - Zinsmeister, Alan R.

AU - Helou, Emelie

AU - Sandborn, William J.

PY - 2008/11

Y1 - 2008/11

N2 - Background & Aims: The quantitative relationships between instruments and assays that measure clinical, endoscopic, and biologic disease activity in patients with Crohn's disease are poorly characterized. This study evaluated the correlations between the Crohn's Disease Activity Index (CDAI), the Simple Endoscopic Score for Crohn's Disease (SES-CD), serum high-sensitivity C-reactive protein (hsCRP) (both phenotype and genotype) and interleukin-6 (IL-6), and fecal calprotectin and lactoferrin. Methods: A total of 164 patients with Crohn's disease undergoing colonoscopy were enrolled. The CDAI and SES-CD scores, serum hsCRP and IL-6, CRP and IL-6 genotypes, and fecal calprotectin and lactoferrin were measured. Results: There were no significant associations between the CDAI and SES-CD scores (Spearman rank correlation coefficient, 0.15) or between the CDAI scores and the serum concentrations of hsCRP and IL-6, or the fecal concentrations of calprotectin and lactoferrin. In contrast, the serum hsCRP and IL-6 concentrations and the fecal calprotectin and lactoferrin concentrations were significantly higher in patients with more severe endoscopic disease activity (SES-CD score > 7 points) (P < .001 for all comparisons). The CRP 717 mutant homozygote and heterozygote status was associated with significantly lower concentrations of hsCRP (P = .02). There was a trend toward higher hsCRP concentrations in the CRP 286 heterozygous adenine mutant-type mutant genotype, but this did not reach statistical significance. Conclusions: Serum and fecal biomarker concentrations are associated with endoscopic but not clinical disease activity in patients with Crohn's disease. Stimulated hsCRP concentration is affected significantly by select genetic polymorphisms.

AB - Background & Aims: The quantitative relationships between instruments and assays that measure clinical, endoscopic, and biologic disease activity in patients with Crohn's disease are poorly characterized. This study evaluated the correlations between the Crohn's Disease Activity Index (CDAI), the Simple Endoscopic Score for Crohn's Disease (SES-CD), serum high-sensitivity C-reactive protein (hsCRP) (both phenotype and genotype) and interleukin-6 (IL-6), and fecal calprotectin and lactoferrin. Methods: A total of 164 patients with Crohn's disease undergoing colonoscopy were enrolled. The CDAI and SES-CD scores, serum hsCRP and IL-6, CRP and IL-6 genotypes, and fecal calprotectin and lactoferrin were measured. Results: There were no significant associations between the CDAI and SES-CD scores (Spearman rank correlation coefficient, 0.15) or between the CDAI scores and the serum concentrations of hsCRP and IL-6, or the fecal concentrations of calprotectin and lactoferrin. In contrast, the serum hsCRP and IL-6 concentrations and the fecal calprotectin and lactoferrin concentrations were significantly higher in patients with more severe endoscopic disease activity (SES-CD score > 7 points) (P < .001 for all comparisons). The CRP 717 mutant homozygote and heterozygote status was associated with significantly lower concentrations of hsCRP (P = .02). There was a trend toward higher hsCRP concentrations in the CRP 286 heterozygous adenine mutant-type mutant genotype, but this did not reach statistical significance. Conclusions: Serum and fecal biomarker concentrations are associated with endoscopic but not clinical disease activity in patients with Crohn's disease. Stimulated hsCRP concentration is affected significantly by select genetic polymorphisms.

UR - http://www.scopus.com/inward/record.url?scp=55149092209&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55149092209&partnerID=8YFLogxK

U2 - 10.1016/j.cgh.2008.06.010

DO - 10.1016/j.cgh.2008.06.010

M3 - Article

C2 - 18799360

AN - SCOPUS:55149092209

VL - 6

SP - 1218

EP - 1224

JO - Clinical Gastroenterology and Hepatology

JF - Clinical Gastroenterology and Hepatology

SN - 1542-3565

IS - 11

ER -